Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Safety
See how Infanrix hexa compares with a competitor in terms of local and systemic reactions post vaccination
Immune persistence
Infanrix hexa is relied upon globally with 20 years of clinical use and 60 million babies vaccinated*1,2
Among all available hexavalent vaccines, it has the longest follow-up of immune persistence – from infancy all the way through to adolescence1,3–6
All antigens
Infanrix hexa is the only hexavalent DTaP 2+1 vaccination schedule with seven-year follow-up of antibody persistence against all antigens, including pertussis1,3–5
Years of documented overall immune persistence follow-up**,†
This graph has been independently created by GSK from the original data.
Hepatitis B
Infanrix hexa has over 14 years** of documented follow-up in HB1,6
Long-term antibody persistence against hepatitis B was observed in adolescents previously vaccinated with Infanrix hexa 3+1 schedule, with over half of participants still showing levels of anti-HBs above the threshold of protection after 14 years6
Infanrix hexa contains the same HB antigen, at the same dose, as Engerix-B,‡‡1,7 which has 20 years of immune persistence follow-up4,8
Quick links
Need help with this product?
anti-HBc, hepatitis core antibody; anti-HBs, hepatitis B surface antibody; CI, confidence interval; DTaP, acellular diphtheria-tetanuspertussis;
GMC, geometric mean concentration; HB, hepatitis B; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus
*210 million doses/3.5 = 60 million babies vaccinated (divided by 3.5 as the median of the 3+1 and 2+1 schedules)2
**Data not from head-to-head comparison studies
†Data for all antigens together, follow-up data for hepatitis B alone may be longer for some vaccines
††3+1 schedule3
‡‡Monovalent hepatitis B vaccine with the same HBV antigen component as Infanrix hexa1,7
Infanrix hexa safety information1
Contraindications:
Hypersensitivity to the active ingredients or to any of the excipients or residues. Hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B, polio or Hib vaccines, or if the child has experienced and encephalopathy of unknown aetiology, occurring within 7 days following vaccination with pertussis containing vaccine.
Warnings and precautions:
Administration should be postponed in subjects suffering from acute severe febrile illness. A protective immune response may not be elicited in all vaccines. Use with caution if any of the following has occurred in temporal relation to receipt of pertussis-containing vaccine within 48 hours:
- Temperature of > 40.0°C.
- Collapse or shock-like state.
- Persistent, inconsolable crying lasting > 3 hours.
- Convulsions with or without fever, occurring within 3 days of vaccination.
Pregnancy and lactation:
Infanrix hexa is not intended to be used in adults.
Adverse events:
Very Common – Appetite lost, pain, redness, local swelling at injection site (< 50 mm), fever > 38°C, fatigue.
References
- Infanrix hexa local prescribing information.
- GSK data on file; 2022N504338_00;1-1.
- Hexyon SmPC, 2020.
- Poovorawan Y et al. Hum Vaccin Immunother 2012; 8:896–904.
- Zinke M et al. Hum Vaccine 2010; 6:189–193.
- Schwartz TF et al. Hum Vaccin Immunother 2019; 15:235–241.
- Engerix-B Prescribing Information, 2019.
- Poovorawan Y et al. Hum Vaccin Immunother 2013; 9:1679–1684.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via Gulf-KSA.Product-Complaints@gsk.com
Trademarks are property of their respective owners.
©2023 GSK group of companies or its licensor. All rights reserved.
PM-RCH-INH-WCNT-230001 | Date of preparation: February 2023
